Clinical data presented at major oncology conferences, peer-reviewed publications, and company milestones.
ImmunoMet presenting updated data and investment thesis at BIO International 2026, San Diego Convention Center.
Updated Phase 1b/2a PDAC data presented at the ESMO Gastrointestinal Cancers Symposium.
Phase 1b/2a interim data for lixumistat in advanced pancreatic cancer presented at the ASCO Gastrointestinal Cancers Symposium.
Published results of the completed Phase 1 study (NCT03272256) in patients with advanced solid tumours. Safety profile established; no dose-limiting toxicities.
Interim data from the Phase 1b/2a PDAC trial at MD Anderson. Publication in progress.
Further references to be added.
Reach out for the latest clinical data, the investor deck, or media enquiries.
